Despite a considerable amount of effort by different groups to evaluate the genetic traits associated with complex diseases by genome-wide association studies (GWAS), just a few regions, mainly linked to protein-coding genes, were identified. Recently, studies from different groups have implicated new classes of long non-coding RNAs (ncRNAs) to important molecular mechanisms. Additionally, high-throughput transcriptome analyses of different cell types have shown that an unexpected amount of genomic DNA is transcribed. I am writing to propose that the majority of the regions that do not clearly correspond to a 'gene' controlling certain traits might be ncRNAs or other regulatory transcripts that are still unknown. These regions will need to be carefully examined in the future.
Genome-wide association studies (GWAS) represent a powerful genetic tool to test the frequency of common variants and phenotypes for specific diseases. It is mainly based in variations in the genome such as single nucleotide polymorphisms (SNPs) and usually needs large cohorts of individuals to provide consistent conclusions. Larger sample sizes for GWAS translate into higher chances to detect genomic variants linked to specific diseases [1, 2] . However, as reported by Park et al. [2] variants identified in GWAS studies only capture a few percent of the heritability of complex traits. Additionally, the identification of these variations is not straightforward, thus requiring laborious steps to confirm if the identified genetic locus or loci is indeed responsible for the observed phenotype(s).
Different groups have recently reviewed the impact of GWAS in the assessment of the risk of complex diseases [3, 4] . Manolio [3] have emphasized the fact that a total of 600 GWAS studies for more than 150 diseases have generated 800 SNP-trait associations. Most of these associations have a very small effect on complex diseases such as diabetes, Crohn's disease, psychiatric disorders and others [3] . As discussed by Manolio, just a small percentage of the genetic traits identified in most of these studies are mapped to regions containing protein-coding genes ( [1] and Figure 1A ). On the other hand, 80% of these traits fall in intergenic and/or non-coding intronic regions in the human genome [3] . Manolio also discusses that signals falling in large 'gene deserts' are not an artifact and might have a functional influence in complex diseases, although more research is needed to completely understand the significance of these genomic regions [3] . In addition, Singleton et al. [4] have discussed that the advent of new DNA-sequencing technologies will overcome several obstacles posed by current methods. This will enable the evaluation of complete genomes with more sensitivity and reliability aiding Fabricio F. Costa is a research scientist at Children's Memorial Research Center and Northwestern University in Chicago, IL, USA. Dr Costa has published more than 30 peer-reviewed articles in the cancer research, genomics and epigenomics fields and has worked as a consultant for newspapers in the biotech sector. Dr Costa was also a reviewer for approximately 50 articles from different journals, has evaluated different projects for European and South American funding agencies and currently work as a consultant for two research groups in Brazil. Dr Costa's main research interests are the impact of non-coding RNA expression in normal and pathological states with a focus in genomics and epigenetics. in our understanding of the genetic architecture of diseases [4] .
Clearly, second-and third-generation DNAsequencing technologies will allow the evaluation of complete genomes and transcriptomes of individuals and their relatives. There is growing evidence that the emergence of these new approaches will facilitate our understanding on how different loci can be associated with susceptibility to complex diseases [4] . The ENCODE Project, in 2007, has already shown the importance of deeply studying whole genomes [5] . Deep genomic and transcriptomic analyses will definitely help in GWAS mainly because complex disease phenotypes include contributions of rare variants, epigenetic factors, genotype-environment interactions and innumerous genetic variants with small additional effects.
Genomic regions that have little combinatorial effects for a disease may signify that a group of genes in a network-and not single genes-are responsible for the observed phenotype(s), as has been suggested in a recent study using flies [6] . Based on these observations, I am writing to propose that several 'gene deserts' identified in previous GWAS studies could be regions that express functional non-coding RNAs (ncRNAs) (for review see [7] ). Novel DNA-sequencing technologies are already allowing a better coverage of transcriptomes showing that a big part of the genome is transcribed as ncRNAs (for review see [8] ). It is becoming clear that long and small ncRNAs with diverse functions in gene regulation are a common feature of the human transcriptome (for review see [9] ). For example, the ncRNA HOTAIR was Figure 1 : Schematic representation of GWAS regions and their association to disease phenotypes. (A) In the GWAS 1, a genomic region was identified as associated to disease phenotypes segregating in individuals from a specific family. A protein-coding gene was easily linked to a disease by a SNP variation or other genetic marker. These polymorphisms or any other markers can be analyzed in other relatives to verify the degree of penetrance of that specific genetic trait to the disease. (B) In the GWAS 2, a region was also identified in a genomic region that has no annotated 'genes' (a 'gene poor' region). With increasing evidence that ncRNAs and other regulatory regions of the genome can be transcribed and might have important functions, this model suggests that we need to carefully examine traits linked to the so-called 'gene deserts'. Genomic DNA location representation is relative. Colored boxes represent protein-coding genes without introns. Bent arrows indicate the direction of transcription. Red arrows indicate SNPs and other markers identified by GWAS studies. pcRNA, protein-coding RNA; ncRNAs, non-coding RNAs; gDNA, genomic DNA. implicated in gene regulation by controlling chromatin modifications [10] [11] [12] . Additionally, a recent report has shown that long ncRNAs might have important functions that could be linked to tumor suppressor genes such as p53 [13] . A model with transcription factors activating long ncRNAs (that serve as key repressors by physically associating with repressive complexes in the DNA) was proposed based on the results obtained by this study [13] . Furthermore, long ncRNAs show evolutionary conservation, implying that this class of 'genes' represents functional RNA molecules [13] .
These new discoveries indicate that several ncRNAs may be functional and not just 'transcriptional noise' as has been previously speculated. To the early geneticists, a 'gene' was a very abstract entity whose existence reflected the way phenotypes were observed when transmitted between generations. The term 'gene' has been re-evaluated to a broader and contemporary definition that is, but is not limited to, regulatory regions, transcriptional units, active pseudogenes and other functional regions transcribed by genomes [14, 15] . According to Gerstein et al. [16] , the word 'gene' is defined as a union of genomic sequences encoding a coherent set of potentially overlapping functional products. Taken together, the emergence of new definitions for a 'gene' along with additional portions of genomes being transcribed could indicate that GWAS that identify regions without protein-coding genes are not artifacts ( Figure 1B ). This growing evidence leads to the hypothesis that GWAS findings that fall in 'gene deserts' might map to long and/or small RNAs and also to important gene enhancers or regulatory regions with unknown functions [17, 18] . In the past, scientists searching for the genetic basis of diseases or other phenotypic features mainly focused on underlying mutations or other defects exclusively in protein-coding genes rather than in other portions of the genome. It is clear now that this concept is questionable. I propose that regions in the genome other than protein coding should be carefully considered as candidate 'genes' associated to specific diseases and disease phenotype(s) in future studies. Researchers will need to re-evaluate the way they classify a 'gene', and genomic regions that are apparently 'gene poor' may produce important transcripts that will need to be tested by different methods for linkage to diseases. Thus, we will also need to develop novel ways to assess the results obtained by GWAS to avoid excluding these new players and obtain a better understanding of complex diseases.
Key Points
A high percentage of GWAS are unable to identify 'genes'or proteins in genomic regions that segregate with complex diseases. New DNA-sequencing technologies have been able to evaluate complete genomes and transcriptomes and there is growing evidence that 70^90% of eukaryotic genomes is transcribed, with the great majority being non-coding RNAs. The main hypothesis of this letter to the editors is that GWAS that fall into genomic regions with no apparent 'gene' or regulatory region will need to be carefully evaluated for the presence of functional non-coding RNAs. Importantly, researchers will need to develop new approaches to evaluate these regions and their effects in complex disease phenotype(s).
